| Literature DB >> 21078153 |
Sari Karlsson1, Milja Heikkinen, Ville Pettilä, Seija Alila, Sari Väisänen, Kari Pulkki, Elina Kolho, Esko Ruokonen.
Abstract
INTRODUCTION: This prospective study investigated the predictive value of procalcitonin (PCT) for survival in 242 adult patients with severe sepsis and septic shock treated in intensive care.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21078153 PMCID: PMC3219988 DOI: 10.1186/cc9327
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flowchart of the study. PCT, procalcitonin.
Patient data for all study patients and different types of infections
| All patients | Community-acquired | Nosocomial | ||
|---|---|---|---|---|
| Number of patients | 242 | 157/242 (64.9%) | 85/242 (35.1%) | < 0.001 |
| Age in years (SD) | 59.8 (15.4) | 58.2 (15.6) | 62.7 (14.7) | 0.03 |
| Males (percentage) | 165 (68.2%) | 109 (69.4%) | 56 (65.9%) | 0.57 |
| APACHE II score (SD) | 24.0 (9.0) | 23.9 (8.8) | 24.1 (9.5) | 0.93 |
| SAPS II (SD) | 43.8 (16.8) | 42.6 (16.0) | 46.1 (17.9) | 0.22 |
| SOFA on day 1a (SD) | 8.4 (3.6) | 8.5 (3.6) | 8.2 (3.5) | 0.74 |
| SOFAmaxb (SD) | 10.9 (4.3) | 11.0 (4.4) | 10.7 (4.1) | 0.68 |
| Postoperative (percentage) | 63 (26.0%) | 31 (19.7%) | 32 (37.6%) | < 0.01 |
| Chronic renal failure | 4 (1.7%) | 1 (0.6%) | 3 (3.5%) | 0.16 |
| Chronic lung disease | 25 (10.3%) | 17 (10.8%) | 8 (9.4%) | 0.84 |
| Chronic hepatic disease | 13 (5.4%) | 6 (3.8%) | 7 (8.2%) | 0.22 |
| Immunosuppression | 30 (12.4%) | 20 (12.7%) | 10 (11.7%) | 0.80 |
| ICU mortality | 33/242 (13.6%) | 20/157 (12.7%) | 13/85 (15.3%) | 0.58 |
| Hospital mortality | 62/242 (25.6%) | 38/157 (24.2%) | 24/85 (28.2%) | 0.49 |
| Source of infection | ||||
| Pulmonary | 101 (41.7%) | 69 (43.9%) | 32 (37.6%) | 0.34 |
| Intra-abdominal | 77 (31.9%) | 42 (26.8%) | 35 (41.2%) | 0.02 |
| Skin or soft tissue | 24 (9.9%) | 17 (10.8%) | 7 (8.2%) | 0.52 |
| Urinary tract | 11 (4.5%) | 8 (5.1%) | 3 (3.5%) | 0.58 |
| Other | 33 (13.6%) | 24 (15.3%) | 9 (10.6%) | 0.31 |
| Blood cultures | ||||
| Blood cultures taken | 160/242 (66.1%) | 110/157 (70.1%) | 49/85 (57.6%) | |
| Positive blood cultures | 69/160 (43.1%) | 56/110 (50.9%) | 13/49 (26.5%) | |
| Microbes in positive | ||||
| | 13 | 13 | 0 | |
| | 11 | 10 | 1 | |
| | 9 | 9 | 0 | |
| Other Gram-positive | 4 | 4 | 0 | |
| | 14 | 11 | 3 | |
| Other Gram-negative | 13 | 8 | 5 | |
| Yeasts | 4 | 1 | 3 | |
| Mycobacterium | 1 | 0 | 1 | |
| Ongoing antibiotic | 98/242 (40.5%) | 38 (24.2%) | 60 (70.6%) | < 0.001 |
P values refer to patients with community-acquired or nosocomial infections. aSequential Organ Failure Assessment score on the day after study entry. bMaximum Sequential Organ Failure Assessment score. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II; SD, standard deviation.
Procalcitonin concentrations in different patient groups
| Procalcitonin, ng/mL | ||
|---|---|---|
| Day 0 | 72 hours | |
| All patients | 5.0 (1.0-20.1) | 1.3 (0.5-5.8) |
| Septic shock (SOFA 4)a | 6.5 (1.6-29.0) | 2.3 (0.7-7.4) |
| Without septic shock (SOFA 0-3)a | 3.2 (0.9-14.7) | 1.1 (0.3-4.4) |
| Severe acute kidney injury (SOFA 3-4)b | 9.4 (2.4-38.2) | 4.9 (0.9-9.5) |
| Without severe acute kidney injury (SOFA 0-2)b | 4.3 (0.9-16.4) | 1.2 (0.3-4.9) |
| Blood culture-positive infectionc | 15.6 (4.3-43.6) | 5.2 (1.7-8.7) |
| Blood culture-negative infectionc | 2.9 (0.8-12.5) | 1.0 (0.3-4.3) |
| Community-acquired infectiond | 6.6 (1.4-33.2) | 2.4 (0.7-6.5) |
| Nosocomial infectiond | 2.9 (0.8-10.6) | 0.9 (0.2-2.8) |
The data are presented as median (interquartile range). P values refer to differences between patient groups (for example, those with and those without septic shock). aP = 0.020 on day 0 and P = 0.031 at 72 hours; bP = 0.027 on day 0 and P = 0.02 at 72 hours; cP < 0.001 on day 0 and P < 0.001 at 72 hours; dP = 0.001 on day 0 and P = 0.003 at 72 hours. SOFA, Sequential Organ Failure Assessment.
Figure 2Procalcitonin (PCT) concentrations in patients with community-acquired or nosocomial infections. P = 0.001 on day 0 and P = 0.003 at 72 hours between the patient groups. PCT concentrations are shown in logarithmic scale and are presented in nanograms per milliliter.
Figure 3Receiver operating characteristic curve for procalcitonin (PCT) concentration and positive blood culture. Areas under the curve are 0.76 (95% confidence interval [CI] 0.66 to 0.86, P < 0.001) for PCT on day 0 and 0.74 (95% CI 0.64 to 0.84, P < 0.001) for PCT at 72 hours.
Figure 4Change in procalcitonin (PCT) concentration (ΔPCT/PCT on day 0) in hospital survivors and nonsurvivors. Asterisks refer to difference in PCT change. Positive change is defined as decreasing concentrations.